Open innovation: An answer for neglected diseases

Future Medicinal Chemistry

Volumn 2, Issue 9, 2010, Pages 1411-1415

  Kar, Sanchayita ^a  

^a SciClips LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; IVERMECTIN;

DISEASE TRANSMISSION; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG TARGETING; FUNDING; HIGH THROUGHPUT SCREENING; HUMAN; MALARIA; NOTE; PATENT; PRIORITY JOURNAL; MEDICAL RESEARCH; RARE DISEASE;

BIOMEDICAL RESEARCH; DRUG INDUSTRY; HUMANS; RARE DISEASES;

EID: 77956580827     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.230     Document Type: Note

References (13)

1. Chesbrough HW. Open Innovation: The New Imperative For Creating and Profting From Technology. Harvard Business School Press Books, Boston, MA, USA, 24 (2003).
2. HunterJ, Stephens S.Is open innovation the way forward for big pharma? Nat. Rev. Drug Discov. 9, 87-88 (2010).
3. Hu M, Schultz K, Sheu J, Tschopp D. Kellogg school of management report: the innovation gap in pharmaceutical drug discovery & new models for R&D success. (2007).
4. Talaga P. Open innovation share or die. Drug Discov. Today 14, 21-22(2009).
5. Hotez P, Molyneux H, Fenwick A et al. Control of neglected tropical diseases. N. Engl. J. Med. 357, 1018-1027 (2007).
6. Kilama WL. The 10/90 gap in sub-Saharan Africa: resolving inequities in health research. Acta Trop. 112. S8-S15 (2009).
7. Gustavsen K, Hanson C. Progress in public-private partnerships to fght neglected diseases. Health Aff. 28, 1745-1749 (2009).
8. Munos B. Can open-source R&D reinvigorate drug research? Nat. Rev. Drug Discov. 5, 723-729 (2006).
9. Mullin R. Paying attention to neglected diseases: the drugs for neglected diseases initiative is mobilizing public/private partnerships. Chem. Eng. News 87(16), 21-24 (2009).
10. Grose S. Online resource aims to smooth the biomed patent search. Nat. Med. 15, 1242 (2009).
11. Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, Ridley R. Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl. Trop. Dis. 3(8), e440 (2009).
12. Callan B, Iain G. The path to new medicines. Nature 449, 164-165 (2007).
13. Senderovitz T. How open innovation could reinvigorate the pharmaceutical industry with fresh R&D opportunities. Expert Rev. Clin. Pharmacol. 2(6), 585-587 (2009).